The emotional counseling service market is projected to grow from $4.72 billion in 2025 to $21.21 billion by 2030, with a CAGR of 35%. Growth drivers include increased digital therapy adoption, rising mental health infrastructure investments, employer-sponsored services expansion, and focus on adolescent mental health. Leading companies are leveraging AI-based tools and tele-counseling platforms to enhance accessibility and personalized care.

The grief counseling market is projected to grow from $3.67 billion in 2025 to $5.83 billion by 2030 at a CAGR of 9.7%. Growth is driven by increased mental health awareness, expansion of digital support platforms, telehealth adoption, and rising demand for accessible bereavement care. Key players include Cleveland Clinic, LifeStance Health, VITAS Healthcare, and Talkspace.

Presidio appointed Paula Cipollone as Chief Transformation Officer to lead strategic operations and drive AI-powered transformation, focusing on streamlining operations and enhancing customer engagement.

LifeStance Health Group, Inc. reported strong Q1 2025 results, with revenue growth, positive net income, and increased Adjusted EBITDA. The company reiterated its full-year 2025 guidance.

LifeStance Health Group, Inc. reported strong financial results for the fourth quarter and full year 2024, with revenue growth of 16% and 19% respectively. The company also provided guidance for 2025, expecting revenue of $1.40 billion to $1.44 billion.

Wall Street analysts have set a mean price target of $7.93 for LifeStance Health, indicating a potential upside of 26.7%. However, investors should be cautious as price targets can be unreliable and analysts may have business incentives to set overly optimistic targets.

TORONTO, June 27, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B0) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough ventures that transform human wellness, reports that management became aware of an unprecedented settlement between Anson Funds and the United States Securities and Exchange Commission dated June 11, 2024. Lifeist is in the process of carefully reviewing and considering the said settlement and examining all legal options with counsel. The Company will promptly report to shareholders at such time as we have made a determination with counsel. A copy of the settlement is publicly available at https://www.sec.gov/files/litigation/admin/2024/ia-6622.pdf.

The heavy selling pressure might have exhausted for LifeStance Health (LFST) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Mikra completes design of new product that delivers superior clarity of cognition and improved memory in collaboration with Jose Bautista and advances shipment date

SCOTTSDALE, Ariz., May 23, 2024 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation’s largest providers of outpatient mental health care, today announced that management will participate in the following upcoming investor conferences.

SCOTTSDALE, Ariz., May 21, 2024 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (Nasdaq: LFST), one of the nation’s largest providers of virtual and in-person outpatient mental health care, today announced the pricing of a secondary underwritten public offering of 20,000,000 shares of LifeStance’s common stock, par value $0.01 per share (the “Common Stock”) at a public offering price of $6.25 per share, pursuant to a shelf registration statement filed with the Securities and Exchange Commission (the “SEC”). The underwriters will have a 30-day option to purchase up to an additional 3,000,000 shares of Common Stock from certain stockholders of the Company (the “Selling Stockholders”). The Selling Stockholders will receive all of the proceeds from the offering. The Company is not selling any shares of Common Stock in the offering and will not receive any proceeds from the offering.

SCOTTSDALE, Ariz., May 21, 2024 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (Nasdaq: LFST), one of the nation’s largest providers of virtual and in-person outpatient mental health care, today announced that certain stockholders of the Company (the “Selling Stockholders”) intend to offer 20,000,000 shares of LifeStance’s common stock, par value $0.01 per share (the “Common Stock”), pursuant to a shelf registration statement filed with the Securities and Exchange Commission (the “SEC”). The underwriters will have a 30-day option to purchase up to an additional 3,000,000 shares of common stock from the Selling Stockholders. The Selling Stockholders will receive all of the proceeds from the offering. The Company is not selling any shares of Common Stock in the offering and will not receive any proceeds from the offering.